Results 231 to 240 of about 31,613 (261)
SENP1: A perspective from immune cells to disease (Review). [PDF]
Feng X, Wu G, Zeng Q.
europepmc +1 more source
Synthetic inhibition of the SUMO pathway by targeting the SAE1 component via TAK-981 compound impairs growth and chemosensitizes embryonal and alveolar rhabdomyosarcoma cell lines. [PDF]
Codenotti S +5 more
europepmc +1 more source
Two Centrins and Their Posttranslational Modification Modulate the Cell Cycle of Giardia lamblia. [PDF]
Yeo HR, Shin MY, Kim J, Park SJ.
europepmc +1 more source
Cooperation between ZEB2 and SP1 upregulates PD‑L1 and CCL2 to promote the immunosuppressive activity of tumor cells. [PDF]
Ko D +5 more
europepmc +1 more source
The emerging roles of ubiquitin-like modifications in regulating HIV replication and host defense. [PDF]
Yuan J, Wang H, Sun X, Huan C.
europepmc +1 more source
Ubiquitin-like SUMO protease expansion in rice (Oryza sativa)
Sue-ob K +5 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Targeting SUMOylation in cancer
Current Opinion in Oncology, 2021Purpose of review In the article, we focus on the role of SUMOylation in tumorigenesis and cancer-related processes, including Epithelial–mesenchymal transition (EMT), metastasis, resistance to cancer therapies, and antitumor immunity. Clinical perspective on small ubiquitin-like modifier (SUMO) inhibitors will be discussed.
Li Du, Wei Liu, Steven T. Rosen
openaire +2 more sources
SUMOylation in atherosclerosis
Clinica Chimica Acta, 2020Atherosclerosis (AS) is the pathophysiologic basis of many cardiovascular diseases. A number of studies have shown that post-translational modification (PTM) contributes to the initiation and progression of AS. For example, recent studies found that SUMOylation, ie, small ubiquitin-like modifier (SUMO) conjugation to target substrate proteins, was ...
Yi-Zhang Liu +6 more
openaire +2 more sources

